NHS Wegovy Access Questioned

This is a England news story, published by BBC, that relates primarily to Ray news.

England news

For more England news, you can click here:

more England news

Ray news

For more Ray news, you can click here:

more Ray news

drug discoveries news

For more drug discoveries news, you can click here:

more drug discoveries news

BBC news

For more news from BBC, you can click here:

more news from BBC

About the Otherweb

Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about

entire NHS drugs budget

. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest Obesity Healthcare Goals programme news, NHS news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!

long NHS patients

BBC

•

‘I feel blessed to get Wegovy weight-loss jab’ - but can the NHS afford it for all?

Summary

Nutrition label

73% Informative

Ray , 62 , became one of the first patients to receive the weight-loss jab Wegovy on the NHS last year .

He has lost 14kg ( just over two stone) in five months and says he feels 'blessed' to be given the drug.

But the NHS spending watchdog NICE has ruled that each patient can only receive the drug for two years .

Only a tiny proportion of eligible 3.4 million patients in England are getting access to the drugs.

Mounjaro has been dubbed the "King Kong " of weight-loss jabs.

In a key trial, patients lost an average of 21% of bodyweight over eight months .

Unlike Wegovy, no restriction has been put on how long NHS patients can stay on the drug.

But the NHS is going to roll out the drug over 12 years because of concerns it could overwhelm services.

For now, though, the health service doesn't have the resources to treat all those eligible. It means - for years to come - only a minority like Ray will get access on the NHS . The rest will have to pay - or go without..

VR Score

Informative language

Neutral language

Article tone

informal

Language

English

Language complexity

Offensive language

possibly offensive

Hate speech

not hateful